AbiVax Poised For 'Transformational' Q2
Key Clinical Readouts Set To Spur Partnering Talks
Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.
